MDRNA Gets $1M Milestone as It Ekes Value from Non-RNAi Programs

Amylin Pharmaceuticals made the payment under an amended version of the companies’ 2006 deal to develop an intranasal formulation of the diabetes drug exenatide.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories